Canada’s Drug Agency | Drugs, Health Technologies and Systems.
Canada’s Drug Agency | Drugs, Health Technologies and Systems.

Emerging Drugs for Relapsed or Refractory Peripheral T-Cell Lymphoma

Details

Files
Project Status:
Completed
Project Line:
Horizon Scan
Project Sub Line:
Emerging Health Technologies
Project Number:
EH0119-000

This Horizon Scan Bulletin provides information on advanced pipeline drugs intended to treat relapsed or refractory peripheral T-cell lymphoma (RR-PTCL). It describes the characteristics of completed phase II and III trials with published results evaluating drugs to treat RR-PTCL that are not currently approved by Health Canada or are under review.

Files

Emerging Drugs for Relapsed or Refractory Peripheral T-Cell Lymphoma View PDF
Last Updated : December 12, 2023